Renovorx expands scientific advisory board with appointment of michel ducreux, m.d., ph.d.

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of michel ducreux, m.d., ph.d. to the company's scientific advisory board (sab). dr. ducreux is the head of the gastrointestinal oncology unit and gastrointestinal oncology tumor board at gustave roussy, professor of oncology at paris-saclay university in france, and vice-chair of es.
RNXT Ratings Summary
RNXT Quant Ranking